Partner Randy D. Gordon, chair of the Firm’s antitrust and trade regulation practice, authored an article for Law360 regarding the antitrust issues associated with the Bayer-Monsanto deal.
“Bayer can make a credible case that it and Monsanto are not — for the most part — competitors in the two market dimensions that count in any antitrust analysis. First, with respect to product markets, Bayer has focused on herbicides in the agricultural space, whereas Monsanto has focused on seeds and genetic technology.”
Subscribers can access the full article here.
Related Insights
December 12, 2025
Health Care Law Today
Eleventh Circuit Hears Oral Argument in Landmark Constitutional Challenge to False Claims Act’s Qui Tam Provisions
On December 12, the U.S. Court of Appeals for the Eleventh Circuit heard oral argument in U.S. ex rel. Zafirov v. Florida Medical…
December 11, 2025
Foley Viewpoints
Antitrust Risks and Compliance Strategies in Intellectual Property Portfolio Management
This article analyzes how intellectual property portfolio management can simultaneously promote innovation and present potential…
December 11, 2025
Foley Viewpoints
CARB Releases Proposed Regulations for SB 261 and 253
On December 9, 2025, the California Air Resources Board (CARB) released its proposed regulatory text for the initial regulations…